Evaluation of IRDye800CW-nimotuzumab in Lung Cancer Surgery
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, optimal dose and imaging time of the
investigational product, IRDye800CW-nimotuzumab for use as a near infrared imaging probe for
image-guided surgery during lung cancer resection. IRDye800CW-nimotuzumab targets cancer
cells over-expressing EGFR, allowing tumors to be visualized and may help surgeons better
identify cancer during surgery.